These findings suggest that eIF4E is a logical therapeutic target for increasing tumor cell radiosensitivity and overcoming cancer radioresistance, implying that eIF4E-targeting strategies for oral cancer treatment may have clinical utility. The gene discussed is EIF4E; the disease is cancer.